ES2541054T3 - Firmas del resultado clínico en tumores estromales gastrointestinales y método de tratamiento de tumores estromales gastrointestinales - Google Patents

Firmas del resultado clínico en tumores estromales gastrointestinales y método de tratamiento de tumores estromales gastrointestinales Download PDF

Info

Publication number
ES2541054T3
ES2541054T3 ES11785107.1T ES11785107T ES2541054T3 ES 2541054 T3 ES2541054 T3 ES 2541054T3 ES 11785107 T ES11785107 T ES 11785107T ES 2541054 T3 ES2541054 T3 ES 2541054T3
Authority
ES
Spain
Prior art keywords
mrna
homo sapiens
gist
aurka
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11785107.1T
Other languages
English (en)
Spanish (es)
Inventor
Frédéric Chibon
Jean-Michel Coindre
Alain Aurias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INST BERGONIE
Institut National de la Santé et de la Recherche Médicale
Institute Curie
Institut Bergonie
Université de Bordeaux
Original Assignee
INST BERGONIE
Institut National de la Santé et de la Recherche Médicale
Institute Curie
Institut Bergonie
Université de Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INST BERGONIE, Institut National de la Santé et de la Recherche Médicale, Institute Curie, Institut Bergonie, Université de Bordeaux filed Critical INST BERGONIE
Application granted granted Critical
Publication of ES2541054T3 publication Critical patent/ES2541054T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES11785107.1T 2010-10-20 2011-10-20 Firmas del resultado clínico en tumores estromales gastrointestinales y método de tratamiento de tumores estromales gastrointestinales Active ES2541054T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10013806 2010-10-20
EP10013806 2010-10-20
PCT/IB2011/054688 WO2012052954A1 (en) 2010-10-20 2011-10-20 Signatures of clinical outcome in gastro intestinal stromal tumors and method of treatment of gastroinstestinal stromal tumors

Publications (1)

Publication Number Publication Date
ES2541054T3 true ES2541054T3 (es) 2015-07-15

Family

ID=44999817

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11785107.1T Active ES2541054T3 (es) 2010-10-20 2011-10-20 Firmas del resultado clínico en tumores estromales gastrointestinales y método de tratamiento de tumores estromales gastrointestinales

Country Status (7)

Country Link
US (1) US20130288250A1 (enExample)
EP (1) EP2630259B8 (enExample)
JP (1) JP2014501496A (enExample)
CA (1) CA2811744A1 (enExample)
DK (1) DK2630259T3 (enExample)
ES (1) ES2541054T3 (enExample)
WO (1) WO2012052954A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3064594A1 (en) 2015-03-06 2016-09-07 Université de Bordeaux Signature of clinical outcome in uterine smooth muscle tumor analysis, and method of diagnosis thereof
KR101860652B1 (ko) 2015-12-23 2018-05-24 연세대학교 산학협력단 위장관 간질 종양 진단용 마커 및 위장관 간질 종양의 진단 방법
JP6965621B2 (ja) * 2017-08-02 2021-11-10 富士通株式会社 検出プログラム、検出方法及び検出装置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491067A1 (en) * 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
JP2008542345A (ja) * 2005-05-28 2008-11-27 アストラゼネカ アクチボラグ キナゾリン類及びオーロラキナーゼ阻害剤としてのその使用
EP1896462A2 (en) * 2005-05-31 2008-03-12 The Pfahl Family Trust (Dated 9 July 1996) Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases
WO2008045133A2 (en) * 2006-03-03 2008-04-17 Veridex, Llc Molecular assay to predict recurrence of dukes' b colon cancer
WO2008025526A1 (en) * 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Indole derivatives, their manufacture and use as pharmaceutical agents
EP2468887A1 (en) * 2006-12-13 2012-06-27 Oncotherapy Science, Inc. TTK as tumor marker and therapeutic target for lung cancer
PE20090365A1 (es) * 2007-06-14 2009-04-04 Schering Corp Imidazopirazinas como inhibidores de proteina quinasa
US9101631B2 (en) * 2008-12-12 2015-08-11 Georgetown University Combination therapy based on SRC and aurora kinase inhibition for the treatment of cancer

Also Published As

Publication number Publication date
JP2014501496A (ja) 2014-01-23
US20130288250A1 (en) 2013-10-31
WO2012052954A1 (en) 2012-04-26
EP2630259A1 (en) 2013-08-28
DK2630259T3 (en) 2015-07-06
EP2630259B1 (en) 2015-04-15
CA2811744A1 (en) 2012-04-26
EP2630259B8 (en) 2015-05-27

Similar Documents

Publication Publication Date Title
ES3063063T3 (en) Method of predicting cancer prognosis and composition for same
Childs et al. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma
Ramdas et al. miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue
US20140162887A1 (en) Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
PT2714926E (pt) Biomarcadores para o cancro do pulmão
US20160362750A1 (en) Compositions and methods for detecting cancer metastasis
US10208353B2 (en) Biomarkers useful for detection of types, grades and stages of human breast cancer
EP3122905B1 (en) Circulating micrornas as biomarkers for endometriosis
US20180230545A1 (en) Method for the prediction of progression of bladder cancer
CN107614696A (zh) 基因表现图谱以及将其应用于乳癌医疗之方法
TW201120449A (en) Diagnostic methods for determining prognosis of non-small-cell lung cancer
EP2630259B1 (en) Signatures of clinical outcome in gastro intestinal stromal tumors and method of treatment of gastroinstestinal stromal tumors
CN106319062A (zh) 一种用于甲状腺癌辅助诊断或疗效预测的微创试剂盒
CN106715722A (zh) 用于评价化学放射线疗法对鳞状细胞癌的有效性的方法
US9708666B2 (en) Prognostic molecular signature of sarcomas, and uses thereof
Mhawech-Fauceglia et al. Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma
WO2018152585A1 (en) "biomarkers for diagnosing conditions"
Jones et al. PLK3 amplification and tumor immune microenvironment of metastatic tumors are linked to adjuvant treatment outcomes in uterine serous cancer
KR20190071081A (ko) 침습성 방광암 진단용 바이오마커
CN113684274B (zh) 用于恶性女性生殖细胞肿瘤诊断和治疗试剂盒
WO2015044495A1 (es) Método para predecir la respuesta al tratamiento con quimioterapia en pacientes de cáncer colorrectal
Feng et al. Genomic and epigenetic instability in chordoma: current insights
CN105505934B (zh) M5型急性髓系白血病相关的特异miRNA及其应用
Mohtasham et al. Comparison of miRNA Profiles of Primary Tumors and Metastatic Tumors of Salivary Gland Tumors and Their Role in Prognosis: A Systematic Review
KR20240067002A (ko) 종양주변 정상조직을 이용한 대장암 예후 예측용 마커